Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
It may be a sign of the times at Havas when it sends out a press release trumpeting retained accounts as new-business wins. Last week, the Paris holding company told the press that Sanofi-Aventis “awarded” Euro RSCG Life “the global advertising account for the thrombosis treatment Lovenox and for Lantus and Apidra diabetes treatment.” It left out one important detail: Euro began working for Lantus in 2003 and has already rolled out the drug in 81 countries, while Lovenox and Apidra were assigned to the agency earlier this year.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in